HUP0301797A3 - Inhibition of angiogenesis and tumor growth - Google Patents

Inhibition of angiogenesis and tumor growth

Info

Publication number
HUP0301797A3
HUP0301797A3 HU0301797A HUP0301797A HUP0301797A3 HU P0301797 A3 HUP0301797 A3 HU P0301797A3 HU 0301797 A HU0301797 A HU 0301797A HU P0301797 A HUP0301797 A HU P0301797A HU P0301797 A3 HUP0301797 A3 HU P0301797A3
Authority
HU
Hungary
Prior art keywords
angiogenesis
inhibition
tumor growth
tumor
growth
Prior art date
Application number
HU0301797A
Other languages
English (en)
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Publication of HUP0301797A2 publication Critical patent/HUP0301797A2/hu
Publication of HUP0301797A3 publication Critical patent/HUP0301797A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
HU0301797A 2000-03-27 2001-03-27 Inhibition of angiogenesis and tumor growth HUP0301797A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19226000P 2000-03-27 2000-03-27
PCT/US2001/009756 WO2001072699A1 (en) 2000-03-27 2001-03-27 Inhibition of angiogenesis and tumor growth

Publications (2)

Publication Number Publication Date
HUP0301797A2 HUP0301797A2 (hu) 2003-09-29
HUP0301797A3 true HUP0301797A3 (en) 2010-09-28

Family

ID=22708924

Family Applications (2)

Application Number Title Priority Date Filing Date
HU0301621A HUP0301621A3 (en) 2000-03-27 2001-03-27 Use of integrin inhibitor for inhibiting angiogenesis and tumor growth
HU0301797A HUP0301797A3 (en) 2000-03-27 2001-03-27 Inhibition of angiogenesis and tumor growth

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HU0301621A HUP0301621A3 (en) 2000-03-27 2001-03-27 Use of integrin inhibitor for inhibiting angiogenesis and tumor growth

Country Status (15)

Country Link
EP (2) EP1272173A4 (hu)
JP (2) JP2003528850A (hu)
KR (2) KR100767616B1 (hu)
CN (2) CN1229339C (hu)
AU (4) AU5101801A (hu)
CA (3) CA2659030A1 (hu)
CZ (2) CZ20023510A3 (hu)
HU (2) HUP0301621A3 (hu)
MX (2) MXPA02009510A (hu)
NO (2) NO328969B1 (hu)
PL (2) PL358272A1 (hu)
RU (2) RU2276133C2 (hu)
SK (2) SK14852002A3 (hu)
WO (2) WO2001072699A1 (hu)
ZA (2) ZA200208628B (hu)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2315721T5 (es) 2003-10-23 2012-08-24 Otsuka Pharmaceutical Co., Ltd. Formulación de aripiprazol inyectable estéril de liberación controlada y procedimiento
UA97286C2 (ru) 2007-07-31 2012-01-25 Оцука Фармасьютикал Ко., Лтд. Способ изготовления суспензии арипипразола и лиофилизированного состава

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8311286D0 (en) * 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
JPH05125029A (ja) 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
GB9308695D0 (en) * 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
GB9405076D0 (en) * 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors
AUPO104496A0 (en) * 1996-07-17 1996-08-08 Biomolecular Research Institute Limited Angiogenic inhibitory compounds
KR20000068415A (ko) * 1996-09-04 2000-11-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 매트릭스 메탈로프로테이나제 억제용 화합물 및 방법
EP0968423A4 (en) * 1997-02-07 2002-10-30 Scripps Research Inst CONVERGENT SYNTHESIS OF COMBINATORIAL BANKING
KR100596109B1 (ko) * 1998-03-27 2006-07-05 제넨테크, 인크. Ｃｄ11/ｃｄ18 부착 수용체 매개 질환 치료용 길항제

Also Published As

Publication number Publication date
CA2403630C (en) 2009-05-26
JP2003528850A (ja) 2003-09-30
RU2276133C2 (ru) 2006-05-10
CA2659030A1 (en) 2001-10-04
EP1272173A4 (en) 2006-05-03
CN1245967C (zh) 2006-03-22
EP1272173A1 (en) 2003-01-08
AU2001251018B2 (en) 2005-12-01
WO2001072699A1 (en) 2001-10-04
MXPA02009504A (es) 2003-05-21
AU4949901A (en) 2001-10-08
CZ20023510A3 (cs) 2003-03-12
KR20020091156A (ko) 2002-12-05
KR20020084258A (ko) 2002-11-04
AU2001249499B2 (en) 2005-04-21
CA2403630A1 (en) 2001-10-04
AU5101801A (en) 2001-10-08
NO20024578L (no) 2002-11-20
CZ20023509A3 (cs) 2003-06-18
SK14852002A3 (sk) 2003-06-03
CA2403871C (en) 2010-05-11
ZA200208626B (en) 2004-02-16
NO20024576L (no) 2002-11-20
CA2403871A1 (en) 2001-10-04
CN1229339C (zh) 2005-11-30
PL358272A1 (en) 2004-08-09
RU2269339C2 (ru) 2006-02-10
CN1429106A (zh) 2003-07-09
CN1441777A (zh) 2003-09-10
PL366316A1 (en) 2005-01-24
KR100767616B1 (ko) 2007-10-18
NO328969B1 (no) 2010-06-28
SK14842002A3 (sk) 2003-04-01
KR100776185B1 (ko) 2007-11-16
JP2003528140A (ja) 2003-09-24
HUP0301621A2 (hu) 2003-09-29
NO20024576D0 (no) 2002-09-24
NO20024578D0 (no) 2002-09-24
WO2001072297A1 (en) 2001-10-04
EP1276713A1 (en) 2003-01-22
HUP0301621A3 (en) 2009-06-29
RU2002128751A (ru) 2004-03-10
HUP0301797A2 (hu) 2003-09-29
EP1276713A4 (en) 2006-05-03
PL205134B1 (pl) 2010-03-31
ZA200208628B (en) 2004-02-12
MXPA02009510A (es) 2003-05-21

Similar Documents

Publication Publication Date Title
EP1097165A4 (en) NEW INHIBITORS OF ANGIOGENESIS AND TUMOR GROWTH
AU2001296558A1 (en) Inhibitors of angiogenesis and tumor growth for local and systemic administration
AU2001256975A1 (en) Compositions and methods for inhibition of cancer invasion and angiogenesis
AU6147401A (en) Compositions and methods for the treatment of cancer
IL178864A0 (en) 3'-prodrugs of 2'-deoxy-??-l-nucleosides
AU2600800A (en) Promotion or inhibition of angiogenesis and cardiovascularization
EP1320376A4 (en) TREATMENT OF PROSTATE CANCER
EP1083928A4 (en) METHOD FOR INHIBITING VASULATION AND TUMOR GROWTH AND FOR PREVENTING TUMOR AND METASTASE GROWTH
AU2596700A (en) Promotion or inhibition of angiogenesis and cardiovascularization
EP1294949A4 (en) HUMAN TUMORNESCROSE FACTOR DELTA AND EPSILON
AU5000001A (en) Treatment of vitiligo
HRP20020729A2 (en) Treatment of psoriasis
AU5101801A (en) Inhibition of angiogenesis and tumor growth
HK1053825B (zh) 酰胼和烷氧基酰胺血管發生抑制劑
AU2001296448A1 (en) Tumor marker and methods of use
IL149281A0 (en) Treatment of cancer
IL141537A0 (en) Promotion or inhibition of angiogenesis and cardiovascularization
AU2001268670A1 (en) Erk-5 deficient animals and methods of inhibiting angiogenesis through the inhibition of erk-5
AU2001261031A1 (en) Inhibition of bone tumor formation using antisense cdna therapy
AU1310201A (en) Cdt6 can inhibit angiogenesis and tumor growth, and can induce or enhance the formation of structures containing collagen
IL142742A0 (en) Promotion or inhibition of angiogenesis and cardiovascularization
TW422400U (en) Improvement of transformer
AU1747100A (en) Promotion or inhibition of angiogenesis and cardiovascularization
GB9824794D0 (en) Inhibition of cytokine production
GB9801391D0 (en) Inhibition of cytokine production

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished